GlassScriptPhysician profile
Vinh Nguyen
NPI 1295231868
$3,835.70
in general payments reported to CMS, 2019-2025
16 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.17 · 2022: $243 · 2023: $1,100 · 2024: $995 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.71 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,242.22 | 2022-2025 | Fasenra, Tezspire |
| Genzyme Corporation | $659.03 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $595.27 | 2024-2025 | Dupixent |
| Alk-Abello, INC | $258.10 | 2023-2025 | Ragwitek, Odactra, Grastek |
| Grifols USA, LLC | $167.42 | 2024 | Xembify |
| Blueprint Medicines Corporation | $131.81 | 2023-2025 | Ayvakit |
| Pharming Healthcare, INC. | $129.95 | 2023-2025 | Ruconest, Joenja |
| Sanofi US Services INC. | $125.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.44 | 2023-2025 | Takhzyro |
| Glaxosmithkline, LLC. | $120.19 | 2024-2025 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $82.80 | 2025 | Neffy |
| Csl Behring | $72.01 | 2023 | Hizentra |
| Biocryst US Sales Co., LLC | $49.79 | 2024-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $38.40 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $26.10 | 2025 | Sajazir |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $14.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinh Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.